Incyte Corp at JPMorgan Healthcare Conference Transcript
All right. Good morning, everyone. Thanks for being here. What I want to try to do with our time this morning is give you a clear and balanced picture of Incyte and talk about how we're thinking about building the company. As I was walking in the room, someone asked me what makes Incyte unique?
The way I think about it is we're not a diversified giant or a small start-up. We have the innovation and growth potential of a biotech company and the capabilities and resources of a large pharma company. I would say the sweet spot of scale. What we're trying to solve for right now is top-tier revenue growth and durable revenue earnings and cash flow. Now in order to navigate the transition of Incyte from a Jakafi company to a hem/onc and IAI company, we have to do these three things right.
You see them on the slide. First, scientific innovation. As you know, return on R&D investment in biopharma has been stubbornly challenging and persistently difficult to unlock. And Incyte is not necessarily immune to that reality. But
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
